ライフサイエンスコーパス: AstraZeneca

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 earch; the SAILS trial was also supported by AstraZeneca.

2 (GNT300755, GNT569213), Sanofi-Aventis, and AstraZeneca.

3 n, Danish Lung Foundation, Velux Foundation, AstraZeneca.

4 earch Council Australia, Sanofi-Aventis, and AstraZeneca.

5 a, National Gynecological Cancer Centre, and AstraZeneca.

6 ded-release metoprolol succinate (Toprol-XL, AstraZeneca) 200 mg or 50 mg or placebo for 12 months.

7 PRIMARY FUNDING SOURCE: AstraZeneca and Bristol-Myers Squibb.

8 mber G1000417/94909), ICON, GlaxoSmithKline, AstraZeneca, and the Medical Evaluation Unit.

9 eveal a competitive relationship between the AstraZeneca (AZ) GSMs and the established second generat

10 tive Board, Region Vastra Gotaland (Sweden), AstraZeneca, Boehringer Ingelheim (Canada), Pfizer (Cana

11 e COPD Foundation through contributions from AstraZeneca, Boehringer Ingelheim, Novartis, and Sepraco

12 e COPD Foundation through contributions from AstraZeneca, Boehringer Ingelheim, Novartis, and Sepraco

13 rch, Heart and Stroke Foundation of Ontario, AstraZeneca (Canada), Sanofi-Aventis (France and Canada)

14 rch, Heart and Stroke Foundation of Ontario, AstraZeneca (Canada), Sanofi-Aventis (France and Canada)

15 ugh the Mary-Jean Mitchell Green Foundation, AstraZeneca, Cancer Research UK, and the National Instit

16 city was tested by cell pretreatment with an AstraZeneca CCR3 antagonist (10(-8) - 10(-6) M).

17 A virtual screen of a subsection of the AstraZeneca compound collection was performed for checkp

18 4- and 1,3,4-oxadiazole matched pairs in the AstraZeneca compound collection.

19 Whole-cell high-throughput screening of the AstraZeneca compound library against the asexual blood s

20 The AstraZeneca compound selectively inhibited these CCL24-m

21 From the phenotypic screening of the AstraZeneca corporate compound collection, N-aryl-2-amin

22 AstraZeneca, Experimental Cancer Medicine Centre, Prosta

23 The cases against TAP and AstraZeneca have been followed by federal and state inve

24 st TAP Pharmaceuticals (Lake Forest, IL) and AstraZeneca International (London, United Kingdom), each

25 In the accompanying paper, a team at AstraZeneca led by Jason G.

26 ere administered the NKB antagonist AZD4901 (AstraZeneca, London, UK) 40 mg orally twice daily for 5

27 o placebo or beta(1)-AR blockade (Toprol-XL, AstraZeneca, London, United Kingdom) for 2 years.

28 , NY) with either gefitinib (Iressa, ZD1839; AstraZeneca, Macclesfield, UK) or erlotinib (Tarceva, OS

29 o receive two years of candesartan (Atacand, AstraZeneca) or placebo, followed by two years of placeb

30 nce between M. D. Anderson Cancer Center and AstraZeneca Pharmaceuticals LP, a concerted effort has b

31 AbbVie Inc., AstraZeneca Pharmaceuticals LP, NIH.

32 US National Cancer Institute and AstraZeneca Pharmaceuticals LP.

33 US National Cancer Institute, AstraZeneca Pharmaceuticals.

34 A biochemical screen of AstraZeneca's compound library using GlmU of Escherichia

35 ncil Australia, Breast Cancer Research Fund, AstraZeneca, Sanofi Aventis.

36 British Heart Foundation, Pfizer, AstraZeneca, Schering-Plough, National Institute for Hea

37 e of Health Research, The Medicines Company, AstraZeneca, The Bentley Drivers Club (UK).

38 tiftung, Wellcome Trust, Cancer Research UK, AstraZeneca UK, University Hospitals of Leicester, Unive

39 er Research UK, UK Medical Research Council, AstraZeneca UK, US Army, EU-Biomed.

40 hip, National Institute for Health Research, AstraZeneca-University of Manchester Strategic Alliance

41 One PARP inhibitor, olaparib (Lynparza, AstraZeneca), was recently approved by the FDA to treat

42 pivotal phase II trial of gefitinib (Iressa; AstraZeneca, Wilmington, DE) conducted in the United Sta

43 ies indicate that gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington, DE), an orally active epidermal

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。